Want to see HK:1477 full AI Analyst Report?
Ocumension Therapeutics (1477) Ratios
Ocumension Therapeutics Ratios
HK:1477's free cash flow for Q2 2026 was $-17.40M. For the 2026 fiscal year, HK:1477's free cash flow was decreased by $-13.39M and operating cash flow was $-4.01M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.70 | 6.31 | 3.82 | 5.88 | 8.50 |
| Quick Ratio | 3.46 | 6.02 | 3.72 | 5.78 | 8.48 |
| Cash Ratio | 1.57 | 4.70 | 2.67 | 4.72 | 5.21 |
| Solvency Ratio | -0.04 | -0.96 | -0.92 | -1.23 | -1.12 |
| Operating Cash Flow Ratio | -0.41 | -1.15 | -0.56 | -0.81 | -0.91 |
| Short-Term Operating Cash Flow Coverage | -2.02 | -86.98 | -1.48 | 0.00 | 0.00 |
| Net Current Asset Value | $ 541.06M | $ 778.61M | $ 854.60M | $ 1.16B | $ 1.61B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.05 | 0.01 | 0.04 | 0.01 | 0.00 |
| Debt-to-Equity Ratio | 0.05 | 0.01 | 0.05 | 0.01 | 0.00 |
| Debt-to-Capital Ratio | 0.05 | 0.01 | 0.05 | 0.01 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.11 | 1.05 | 1.12 | 1.11 | 1.07 |
| Debt Service Coverage Ratio | -0.31 | -44.81 | -2.65 | -201.00 | -219.75 |
| Interest Coverage Ratio | -67.26 | -141.67 | -303.51 | -254.25 | -679.37 |
| Debt to Market Cap | 0.03 | 0.01 | 0.03 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.24 | 0.04 | 0.21 | 0.05 | 0.02 |
| Net Debt to EBITDA | 13.06 | 3.74 | 2.20 | 3.17 | 4.46 |
| Profitability Margins | |||||
| Gross Profit Margin | 44.87% | 53.93% | 58.60% | 64.74% | 65.78% |
| EBIT Margin | -19.92% | -63.52% | -153.49% | -251.91% | -462.05% |
| EBITDA Margin | -2.05% | -45.06% | -130.14% | -226.46% | -444.92% |
| Operating Profit Margin | -19.92% | -73.43% | -163.23% | -286.78% | -686.07% |
| Pretax Profit Margin | -19.70% | -64.04% | -154.03% | -253.04% | -463.06% |
| Net Profit Margin | -19.75% | -64.29% | -154.15% | -253.30% | -463.06% |
| Continuous Operations Profit Margin | -19.75% | -64.29% | -154.15% | -253.30% | -463.06% |
| Net Income Per EBT | 100.22% | 100.38% | 100.08% | 100.10% | 100.00% |
| EBT Per EBIT | 98.92% | 87.22% | 94.36% | 88.23% | 67.49% |
| Return on Assets (ROA) | -3.88% | -6.75% | -11.61% | -13.23% | -7.81% |
| Return on Equity (ROE) | -4.31% | -7.11% | -13.01% | -14.65% | -8.36% |
| Return on Capital Employed (ROCE) | -4.18% | -8.02% | -13.61% | -16.30% | -12.37% |
| Return on Invested Capital (ROIC) | -4.11% | -8.01% | -13.02% | -16.23% | -6.40% |
| Return on Tangible Assets | -10.65% | -17.47% | -17.82% | -18.95% | -9.92% |
| Earnings Yield | -3.02% | -9.23% | -9.67% | -7.35% | -3.00% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.37 | 2.54 | 29.33 | 1.41 | 3.03 |
| Payables Turnover | 2.31 | 5.59 | 4.05 | 2.58 | 4.36 |
| Inventory Turnover | 6.93 | 4.22 | 3.14 | 2.32 | 3.85 |
| Fixed Asset Turnover | 1.76 | 0.92 | 0.53 | 0.35 | 0.15 |
| Asset Turnover | 0.20 | 0.11 | 0.08 | 0.05 | 0.02 |
| Working Capital Turnover Ratio | 1.06 | 0.49 | 0.23 | 0.11 | 0.03 |
| Cash Conversion Cycle | 49.04 | 164.58 | 38.50 | 274.45 | 131.46 |
| Days of Sales Outstanding | 154.18 | 143.51 | 12.44 | 258.81 | 120.33 |
| Days of Inventory Outstanding | 52.63 | 86.42 | 116.20 | 156.99 | 94.86 |
| Days of Payables Outstanding | 157.77 | 65.35 | 90.15 | 141.35 | 83.73 |
| Operating Cycle | 206.81 | 229.93 | 128.64 | 415.80 | 215.19 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.13 | -0.26 | -0.27 | -0.32 | -0.32 |
| Free Cash Flow Per Share | -0.45 | -0.59 | -0.83 | -0.81 | -1.42 |
| Dividend Paid and CapEx Coverage Ratio | -0.42 | -0.78 | -0.49 | -0.65 | -0.30 |
| Capital Expenditure Coverage Ratio | -0.42 | -0.78 | -0.49 | -0.65 | -0.30 |
| Operating Cash Flow Coverage Ratio | -0.56 | -6.94 | -1.29 | -6.78 | -17.56 |
| Operating Cash Flow to Sales Ratio | -0.13 | -0.43 | -0.72 | -1.26 | -3.51 |
| Free Cash Flow Yield | -6.82% | -14.07% | -13.74% | -9.32% | -9.96% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -33.23 | -10.84 | -10.35 | -13.61 | -33.28 |
| Price-to-Sales (P/S) Ratio | 6.54 | 6.97 | 15.95 | 34.47 | 154.12 |
| Price-to-Book (P/B) Ratio | 1.43 | 0.77 | 1.35 | 1.99 | 2.78 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -14.66 | -7.11 | -7.28 | -10.73 | -10.04 |
| Price-to-Operating Cash Flow Ratio | -49.95 | -16.26 | -22.08 | -27.31 | -43.96 |
| Price-to-Earnings Growth (PEG) Ratio | 0.68 | 0.32 | 1.32 | -0.28 | 0.35 |
| Enterprise Value Multiple | -306.24 | -11.72 | -10.06 | -12.05 | -30.18 |
| Enterprise Value | 5.04B | 2.20B | 3.22B | 4.34B | 7.54B |
| EV to EBITDA | -306.24 | -11.72 | -10.06 | -12.05 | -30.18 |
| EV to Sales | 6.27 | 5.28 | 13.09 | 27.29 | 134.27 |
| EV to Free Cash Flow | -14.06 | -5.39 | -5.97 | -8.50 | -8.75 |
| EV to Operating Cash Flow | -47.90 | -12.32 | -18.12 | -21.62 | -38.30 |
| Tangible Book Value Per Share | 1.37 | 1.94 | 2.74 | 2.89 | 3.95 |
| Shareholders’ Equity Per Share | 4.65 | 5.49 | 4.50 | 4.35 | 5.12 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.00 | -0.00 | -0.00 | 0.48 |
| Revenue Per Share | 1.02 | 0.61 | 0.38 | 0.25 | 0.09 |
| Net Income Per Share | -0.20 | -0.39 | -0.59 | -0.64 | -0.43 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.99 | 1.01 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.09 | 0.27 | 0.50 | 1.16 | 3.01 |
| SG&A to Revenue | 0.55 | 0.65 | 0.80 | 1.20 | 2.25 |
| Stock-Based Compensation to Revenue | 0.09 | 0.20 | 0.57 | 1.38 | 3.35 |
| Income Quality | 0.66 | 0.67 | 0.47 | 0.50 | 0.76 |
Currency in CNY